glp-1 drugs glycemic control mechanism for Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? GLP-1 Therapy Part 1: Setting

Market perspective Fast-track approval reflects urgency in tackling obesity Oral therapies may capture ~20% of the market by 2030 Expands access for patients preferring pills over injections While Novo Nordisk may offer slightly higher weight loss with its oral option, ease of use and flexibility position this therapy as a strong competitor

Bioavailability can be determined from the ratio of the areas under the concentrationtime curves for an identical bolus dose given both orally and intravenously (Figure 2.1)

1 Separating Myth from Fact Myth : Anyone can take GLP-1 weight-loss drugs

A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: randomized, placebo-controlled, double-blind clinical trial